ClinicalTrials.gg

Program

palbociclib

Also written as “Palbociclib”, “PD-0332991” and “Palbociclib 125mg”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Sarcoma, Ewing · Squamous Cell Carcinoma of Head and Neck · COVID-19, led by 7 companies.

Furthest: phase 4, since Jan 22, 201635 company-led studies, 4 open or runningNext primary completion: Dec 22, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer291 open or runningphase 4since Jan 22, 2016Aug 30, 2005Dec 31, 2029phase 2 · NCT05226871
biotx.ai10 open or runningphase 2since Apr 26, 2022Apr 26, 2022none ahead
Criterium11 open or runningphase 2since Sep 3, 2020Sep 3, 2020Dec 31, 2027phase 2 · NCT04567420
CSPC Pharmaceutical Group11 open or runningphase 1since Apr 16, 2025Apr 16, 2025Oct 2027phase 1 · NCT06941142
iOMEDICO10 open or runningphase 2since Aug 25, 2016Aug 25, 2016none ahead
Megalabs10 open or runningphase 4since Mar 19, 2024Mar 19, 2024none ahead
Merck11 open or runningphase 2since Jul 18, 2022Jul 18, 2022Dec 22, 2026phase 2 · NCT05468697

Also a collaborator on its studies: AstraZeneca and Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 20 studies since Aug 30, 2005.

  1. Jan 6, 2015Phase 1 study in Hepatic InsufficiencyPfizer · NCT02334800 · 28 enrolled · United States
  2. Jul 13, 20152 phase 1 studiesPfizer · NCT02499146, NCT02501902
  3. Jul 13, 2015Phase 2 study in Squamous Cell Carcinoma of Head and NeckPfizer · NCT02499120 · 125 enrolled · United States, Czechia, Hungary and more
  4. Nov 6, 2015Phase 3 study in Breast NeoplasmsPfizer · NCT02600923 · 131 enrolled · Argentina, Brazil, Colombia and more
  5. Jan 22, 2016Phase 4 study in Breast NeoplasmsPfizer · NCT02679755 · 252 enrolled · Australia, India
  6. Aug 25, 2016iOMEDICO's first study: phase 2 study in Breast NeoplasmsNew to iOMEDICOiOMEDICO · NCT02894398 · 388 enrolled · Germany
  7. Jun 16, 2017Phase 1 study in Healthy VolunteerPfizer · NCT03220191 · 12 enrolled · United States
  8. Oct 9, 2018Phase 2 study in Sarcoma, EwingPfizer · NCT03709680 · 128 enrolled · United States, Brazil, Canada and more
  9. Sep 3, 2020Criterium's first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04567420 · 70 enrolled · United States
  10. Jan 26, 2022Phase 2 study in Breast NeoplasmsPfizer · NCT05226871 · 35 enrolled · United States, China, Mexico and more
  11. Apr 26, 2022biotx.ai's first study: phase 2 study in COVID-19New to biotx.aibiotx.ai · NCT05371275 · Germany
  12. Jul 18, 2022Merck's first study: phase 2 study in Carcinoma, Renal CellNew to MerckMerck · NCT05468697 · 60 enrolled · United States, Australia, Israel
  13. Mar 19, 2024Megalabs's first study: phase 4 study in BioequivalenceNew to MegalabsMegalabs · NCT06331715 · 24 enrolled · India
  14. Apr 16, 2025CSPC Pharmaceutical Group's first study: phase 1 study in Advanced Breast CancerNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06941142 · 382 planned

Ahead

  1. Dec 22, 2026Primary completion: phase 2 study in Carcinoma, Renal CellMerck · NCT05468697
  2. Oct 2027Primary completion: phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142
  3. Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsCriterium · NCT04567420
  4. Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsPfizer · NCT05226871

TargetBeta

“CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor”ChEMBL 37, by rule

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06941142Advanced Breast Cancer1Not yet recruitingCSPC Pharmaceutical GroupOct 2027382
NCT06331715Bioequivalence · India4CompletedMegalabsApr 1, 202424
NCT05468697Carcinoma, Renal Cell · United States, Australia, Israel2Active, not recruitingMerckDec 22, 202660
NCT05371275COVID-19 · Germany2Withdrawnbiotx.aiOct 20220
NCT05226871Breast Neoplasms · United States, China, Mexico and more2Active, not recruitingPfizerDec 31, 202935
NCT04567420Breast Neoplasms · United States2Active, not recruitingCriteriumDec 31, 202770
NCT03709680Sarcoma, Ewing · United States, Brazil, Canada and more2CompletedPfizerAug 26, 2024128
NCT03220191Healthy Volunteer · United States1CompletedPfizerSep 3, 201712
NCT02894398Breast Neoplasms · Germany2CompletediOMEDICOFeb 15, 2023388
NCT02679755Breast Neoplasms · Australia, India4CompletedPfizerJul 25, 2019252
NCT02600923Breast Neoplasms · Argentina, Brazil, Colombia and more3CompletedPfizerMay 28, 2019131
NCT02501902Metastatic Pancreatic Ductal Adenocarcinoma · United States, Spain1CompletedPfizerOct 10, 201876
NCT02499146Advanced Breast Cancer · China1CompletedPfizerJul 31, 201826
NCT02499120Squamous Cell Carcinoma of Head and Neck · United States, Czechia, Hungary and more2CompletedPfizerJul 19, 2018125
NCT02334800Hepatic Insufficiency · United States1CompletedPfizerOct 9, 201628
NCT02311946Healthy · United States1CompletedPfizerApr 201560
NCT02297438Breast Neoplasms · China, Hong Kong, Singapore and more3CompletedPfizerAug 31, 2020340
NCT02222441Healthy · United States1CompletedPfizerDec 201414
NCT02131298Healthy · United States1CompletedPfizerJun 201412
NCT02085538Renal Insufficiency · United States1CompletedPfizerMay 201631
NCT02059330Healthy · United States1CompletedPfizerJun 201427
NCT01953731Healthy · United States1CompletedPfizerJan 201415
NCT01942135Breast Neoplasms · United States, Australia, Belgium and more3CompletedPfizerDec 5, 2014521
NCT01918176Healthy · United States1CompletedPfizerDec 201326
NCT01906125Healthy · United States1CompletedPfizerJan 201473
NCT01821066Healthy · United States1CompletedPfizerAug 201325
NCT01802476Healthy · United Kingdom1CompletedPfizerJun 201314
NCT01756781Healthy · United States1CompletedPfizerJul 201326
NCT01740427Breast Neoplasms · United States, Australia, Belgium and more3CompletedPfizerFeb 26, 2016666
NCT01684215Neoplasms · Japan2CompletedPfizerMar 4, 201661
NCT01602887Breast Neoplasms · United States1CompletedPfizerNov 201224
NCT00721409Breast Neoplasms · United States, Canada, France and more2CompletedPfizerNov 29, 2013177
NCT00555906Multiple Myeloma · United States, Czech Republic, Germany2CompletedPfizerAug 201253
NCT00420056Lymphoma, Mantle-Cell · United States1CompletedPfizerMar 201017
NCT00141297Neoplasms · United States1CompletedPfizerJul 200874

How it is read

Names in the registry

  • “Palbociclib”, 16 entries
  • “PD-0332991”, 12 entries
  • “palbociclib”, 5 entries
  • “Palbociclib 125mg”, 3 entries
  • “Palbociclib alone”, 3 entries

Codes read as this program: PD0332991.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.